1. Cardiometabolic Risk in Type 2 Diabetes: What Can the PPAR-g Agonists Teach Us?

2. UKPDS 35: Impact of Increasing A1c on Cardiovascular Disease in T2DM

3. Insulin Resistance Is Associated With or Directly Responsible for Factors Causing Atherothrombosis

4. UKPDS 35: Effect of A1c on MI and Microvascular Events

5. UKPDS 80: 10-Year Follow-up Study of Intensive Glycemic Control in T2DM

6. Incidence of CV Events in Subjects With T2DM vs the Nondiabetic CAD Population

7. PPAR-g Agonists: Lipoprotein Effects

8. PROactive: Time to Secondary CV Composite End Point

9. FDA Statistical Review and Evaluation Meta-analysis of Pioglitazone

10. CV Events With PPAR-g Agonists

11. Genes Uniquely Regulated by the TZDs

12. Pioglitazone Induces IkBa Protein Expression In Vivo in a PPAR-a-Dependent Manner

13. The Concept of Dual PPAR-a/g Agonists

14. Effect of Muraglitazar on Composite CV Endpoints

15. Effect of Tesaglitazar on Serum Creatinine and Glomerular Filtration

16. SYNCHRONY: Effect of Aleglitazar vs Pioglitazone on A1c

17. SYNCHRONY: Effect of Aleglitazar vs Pioglitazone on LDL-C and HDL-C

18. ALECARDIO: Aleglitazar in Patients With T2DM and ACS

19. Program Summary